|
|
| Year:
2019 |
Month:
July
|
Volume:
8 |
Issue:
3 |
Page:
PO01 - PO04 |
Intensity and Grading of Galectin-3 Expression as a Sole Marker to Differentiate Benign and Malignant Thyroid Neoplasms
|
| |
Correspondence
Pallavi Vijay Borkar, Kondisetty Gowrinath, Kondisetty Sandeep,
Dr. Kondisetty Gowrinath,
Assistant Professor, Department of General Surgery, Medicity Institute of Medical Sciences,
Ghanpur, Medchal, Telangana, India.
E-mail: docsunnyhyd@gmail.com :
|
 |
Introduction: Errors in categorization of thyroid neoplasms as benign or malignant has management implications. In several studies Galectin-3 was one of the most reliable markers for malignancy in thyroid.
Aim: To evaluate utility of Galectin-3 as a sole marker in differentiating benign and malignant thyroid neoplasm.
Materials and Methods: Forty one thyroidectomy cases were studied, which included 12 benign and 29 malignant thyroid neoplasms. Galectin-3 (CELL MARQUE Galectin-3 mouse monoclonal antibody, CMC25521020) expression was assessed. Grading based on intensity and extent (diffuse/focal) of Galectin-3 expression was also noted.
Results: The expression of Galectin-3 was significantly higher (p<0.001) in malignant thyroid neoplasms. Difference in Galectin-3 expression in benign thyroid neoplasms and PTC was significant (p<0.001). Galectin-3 expression within various follicular neoplasms was not useful when only positivity (>10% of cells positive) (p>0.08) and diffuse positivity (>50% of cells positive) (p>0. 0.167) were taken into consideration. However, with grade 3 intensity of Galectin- 3 staining in various follicular neoplasms there was a significant difference in Galectin-3 expression (p<0.002).
Conclusion: Galectin-3 is useful in differentiating benign and malignant thyroid neoplasm (p<0.05). It can be used as sole marker for differentiating Papillary thyroid carcinoma and benign thyroid neoplasms. Grade 3 intensity of Galectin-3 positivity could prove to be a useful marker in differentiating follicular patterned lesions.
|
| |
[ FULL
TEXT ] | [   ]
|
| |
Print
|
|